| Entry |
|
|---|
| Name |
Omarigliptin (JAN/USAN/INN)
|
|---|
| Formula |
C17H20F2N4O3S
|
|---|
| Exact mass |
398.1224
|
|---|
| Mol weight |
398.4275
|
|---|
| Structure |
   |
|---|
| Class |
|
|---|
| Remark |
| Therapeutic category: | 3969 |
|
|---|
| Efficacy |
Antidiabetic, Dipeptidyl peptidase-4 (DPP-4) inhibitor |
|---|
| Disease |
Type 2 diabetes mellitus [DS: H00409] |
|---|
| Comment |
Treatment of type 2 diabetes
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04974 | Protein digestion and absorption |
|
|---|
| Interaction |
|
|---|
| Brite |
Therapeutic category of drugs in Japan [BR:br08301]
3 Agents affecting metabolism
39 Other agents affecting metabolism
396 Antidiabetic agents
3969 Others
D10317 Omarigliptin (JAN/USAN/INN)
Target-based classification of drugs [BR:br08310]
Enzymes
Hydrolases (EC3)
Peptidyl-peptidases
DPP4 (CD26)
D10317 Omarigliptin (JAN/USAN/INN) <JP>
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D10317
 |
|---|
| Other DBs |
|
|---|
| LinkDB |
 |
|---|
| KCF data |
ATOM 27
1 C8y C 12.3200 -18.3400
2 C8y C 12.3200 -19.7400
3 C8x C 13.6515 -20.1726
4 N4y N 14.4744 -19.0400
5 N5x N 13.6515 -17.9074
6 C1x C 10.9885 -17.9074
7 N1y N 10.1656 -19.0400
8 C1x C 10.9885 -20.1726
9 S4a S 15.8900 -19.0400
10 O3c O 15.8900 -20.4400
11 O3c O 15.8900 -17.6400
12 C1a C 17.2900 -19.0400
13 C1y C 8.7500 -19.0400
14 C1x C 8.0500 -17.8276
15 C1y C 6.6500 -17.8276
16 C1y C 5.9500 -19.0400
17 O2x O 6.6500 -20.2524
18 C1x C 8.0500 -20.2524
19 C8y C 4.5500 -19.0400
20 C8x C 3.8500 -17.8276
21 C8y C 2.4500 -17.8276
22 C8x C 1.7500 -19.0400
23 C8x C 2.4500 -20.2524
24 C8y C 3.8500 -20.2524
25 X F 4.5404 -21.4479
26 X F 1.7596 -16.6321
27 N1a N 5.9596 -16.6321
BOND 30
1 1 2 1
2 2 3 2
3 3 4 1
4 4 5 1
5 1 5 2
6 1 6 1
7 6 7 1
8 7 8 1
9 2 8 1
10 4 9 1
11 9 10 2
12 9 11 2
13 9 12 1
14 13 7 1 #Up
15 13 14 1
16 14 15 1
17 15 16 1
18 16 17 1
19 17 18 1
20 13 18 1
21 16 19 1 #Down
22 19 20 2
23 20 21 1
24 21 22 2
25 22 23 1
26 23 24 2
27 19 24 1
28 24 25 1
29 21 26 1
30 15 27 1 #Up
|
|---|
